News
News
-
TFBS Bioscience Complete its First Clinical-Grade Manufacturing Batch of Lentiviral Vectors for CAR-T Cell Therapy in Taiwan
2022-08-17
TFBS Bioscience Complete its First Clinical-Grade Manufacturing Batch of Lentiviral Vectors for CAR-T Cell Therapy in Taiwan
- A critical step for TFBS Bioscience to enable the manufacturing of clinical-grade lentiviral vectors in its Taipei facility and ready to supply viral vectors for the global needs of cell and gene therapies
Learn more
-
Center for Drug Evaluation (CDE) to visit TFBS Bioscience, Inc.
2022-04-29
Center for Drug Evaluation (CDE) to visit TFBS Bioscience, Inc.
We are honored to invite the Center for Drug Evaluation (CDE) to visit TFBS Bioscience, Inc. GMP viral vector manufacturing facility.
Learn more
-
TFBS received the official approval letter from US FDA for the pre-approval inspection (PAI)
2022-04-22
TFBS received the official approval letter from US FDA for the pre-approval inspection (PAI)
The US FDA completed a pre-approval inspection (PAI) of TFBS Bioscience’ brand new GMP testing facility on April 22, 2022. No 483 observation is cited. The positive outcome adds further assurance for our newly-established GMP testing business.
Learn more
